Monday, 6 February 2017

MHTP welcomes new Director and Professor of Oncology

Professor Eva Segelov
The Monash Health Translation Precinct (MHTP) welcomes Eva Segelov who commences this week as Director of Oncology at Monash Health and Professor of Oncology in the Department of Medicine, Monash University.

Professor Segelov comes from the University of New South Wales where she was a clinical academic and a senior staff specialist in medical oncology.  She previously worked at the Southwest Sydney Clinical School at Liverpool Hospital and St Vincent’s Clinical School at St Vincent’s Hospital, Sydney.

While her clinical focus has been in the management of patients with breast, upper and lower gastrointestinal cancer and neuroendocrine tumours, Professor Segelov’s research interests are in clinical trials and associated translational research.  She has led multiple national and international trials.

“I am extremely excited to be taking on this new position at MHTP—the mission to lead the transformation of the Medical Oncology Department into a world-class patient-centered academic cancer centre through the links with Monash University was my motivation for moving cities,” said Professor Segelov.

“The MHTP enables research excellence in clinical trials and translational research as well as the opportunity to collaborate with world-renowned colleagues in state-of-the-art facilities.”

“I hope to provide leadership and nurturing to the excellent staff already at Monash Health and MHTP and to grow the clinical trials portfolio and the productivity from the associated research,” said Professor Segelov.

Professor Segelov plans to be a vocal advocate for patient-focussed oncology services and research across the precinct.

As well as serving as a Board member of the Australasian Gastrointestinal Trials Group (AGITG) and Convenor of the AGITG Annual Scientific Meeting, Professor Segelov is the Gastrointestinal Chair for the Clinical Oncology Society of Australia (COSA).  She is also the co-Track Chair for GI Cancer at the ESMO Asia annual conference and the Co-Founder of The Commonwealth Neuroendocrine Tumour Collaboration (CommNETS), an international research organisation between Australia, Canada and New Zealand.

No comments:

Post a Comment